AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

Inclusion bodies, once considered a hindrance in recombinant protein production, are now recognised for their potential as reservoirs of bioactive proteins and functional biomaterials. In bacterial ...

Detailed price information for Dyadic International (DYAI-Q) from The Globe and Mail including charting and trades.

As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...

Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

In addition to OEM distribution, the collaboration provides flexibility for potential future expansion, which could include Dyadic supplying market-ready products for distribution or licensing ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

This article and associated images are based on a poster originally authored by Amy Turner, Poppy Nathan, Yanan Lu, Deepa Shankar, Danielle Callahan, Lion Lian and Jason Li and presented at ELRIG Drug ...